Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 161-167

  Devarbhavi, Harshad ^a   Singh, Rajvir ^b   Patil, Mallikarjun ^a   Sheth, Keyur ^a   Adarsh, Channagiri Krishnamurthy ^a   Balaraju, Girisha ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Drug induced; Hepatitis; Hepatotoxicity; Liver injury; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEPATITIS B SURFACE ANTIGEN; PROTEIN;

ABDOMINAL TUBERCULOSIS; ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM TUBERCULOSIS; CHILD; CLINICAL ASSESSMENT TOOL; CREATININE BLOOD LEVEL; DRUG EXPOSURE; EOSINOPHIL COUNT; FEMALE; GENDER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER FAILURE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RASH; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTE COUNT; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOUS ARTHRITIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS SPONDYLITIS;

EID: 84871667909     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07279.x     Document Type: Article

References (42)

1. World Health Organization Report 2011. Global tuberculosis control.
2. Saukkonen JJ, Cohn DL, Jasmer RM etal. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med. 2006; 174: 935-952.
3. Senousy BE, Belal SI, Draganov PV. Hepatotoxic effects of therapies for tuberculosis. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 543-556.
4. Tostmann A, Boeree MJ, Aarnoustse RE etal. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol. 2008; 23: 192-202.
5. Yee D, Valiquette C, Pelletier M etal. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am. J. Respir. Crit. Care Med. 2003; 167: 1472-1477.
6. Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin. Drug Saf. 2006; 5: 231-249.
7. Shang P, Xia Y, Liu F etal. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 2011; 6: e21836.
8. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur. Respir. J. 1996; 9: 2026-2030.
9. van Hest R, Baars H, Kik S etal. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin. Infect. Dis. 2004; 39: 488-496.
10. Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am. J. Respir. Crit. Care Med. 2003; 167: 809-810.
11. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int. J. Tuberc. Lung Dis. 2002; 6: 995-1000.
12. Chang KC, Leung CC, Yew WW etal. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am. J. Respir. Crit. Care Med. 2008; 177: 1391-1396.
13. Tost JR, Vidal R, Caylà J etal. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int. J. Tuberc. Lung Dis. 2005; 9: 534-540.
14. Devarbhavi H, Karanth D, Prasanna KS etal. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology 2011; 54: 1344-1350.
15. Devarbhavi H, Dierkhising R, Kremers WK etal. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am. J. Gastroenterol. 2010; 105: 2396-2404.
16. Kumar R, Shalimar, Bhatia V etal. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010; 51: 1665-1674.
17. Mitchell I, Wendon J, Fitt S, WillIams R. Anti-tuberculous therapy and acute liver failure. Lancet 1995; 345: 555-556.
18. Andrade RJ, Lucena MI, Fernández MC etal. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
19. Durand F, Bernuau J, Pessayre D etal. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21: 929-932.
20. Chalasani N, Fontana RJ, Bonkovsky HL etal. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
21. Nunn P, Reid A, De Cock KM. Tuberculosis and HIV infection: the global setting. J. Infect. Dis. 2007; 196: S5-14.
22. Devarbhavi H, Kremers W. Fulminant hepatic failure: cause, course and predictors of outcome. Ind. J. Gastroenterol. 2005; 24 (Suppl. 1): A116.
23. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet 1993; 342: 273-275.
24. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002; 25: 111-133.
25. Sharma SK, Singla R, Sarda P etal. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin. Infect. Dis. 2010; 50: 833-889.
26. Kamath PS, Wiesner RH, Malinchoc M etal. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
27. Devarbhavi H, Dierkhising R, Kremers WK. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 2010; 52: 798-799.
28. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 1990; 11: 272-276.
29. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 1993; 46: 1323-1330.
30. Aithal GP, Watkins PB, Andrade RJ etal. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 2011; 89: 806-815.
31. Wu SS, Chao CS, Vargas JH etal. Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation 2007; 84: 173-179.
32. Larson AM, Polson J, Fontana RJ etal. Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372.
33. Murray KF, Hadzic N, Wirth S, Bassett M, Kelly D. Drug-related hepatotoxicity and acute liver failure. J. Pediatr. Gastroenterol. Nutr. 2008; 47: 395-405.
34. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51: 615-620.
35. Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 1999.
36. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
37. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver 'function' tests? Clin. Pharmacol. Ther. 2009; 85: 331-334.
38. Singanayagam A, Sridhar A, Dhariwal J etal. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am. J. Respir. Crit. Care Med. 2012; 185: 653-659.
39. Agal S, Baijal R, Pramanik S etal. Monitoring and management of antituberculosis drug induced hepatotoxicity. J. Gastroenterol. Hepatol. 2005; 20: 1745-1752.
40. Noolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018.
41. Gordin F, Chaisson RE, Matts JP etal. Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000; 283: 1445-1450.
42. Huang YS, Chern HD, Su WJ etal. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.